TUM Department of Nuclear Medicine

The TUM Department of Nuclear Medicine is one of the largest Nuclear Medicine Departments in Europe. The Department has a long-standing experience in performing preclinical and clinical research in molecular imaging as well as therapeutic applications of new radiotheranostic tracers.

A specific strength of the department is the rapid translation of novel molecular imaging technologies to the clinic.

It operates radiochemistry facilities as well as preclinical and clinical imaging facilities for the testing and clinical translation of new radiopharmaceuticals. A description of these facilities and the services that the department offers to PRISMAP users can be found below.

Preclinical facilities

For housing animals treated with beta or alpha-emitting radionuclides. They are equipped with small animal imaging facilities (PET/MRI and SPECT/CT) for in vivo and in vitro characterisation of newly developed tracers.

Chemistry facilities

For radiolabelling with a variety of diagnostic and therapeutic radionuclides, including GMP facilities for clinical studies.

Clinical facilities


These are equipped with a dedicated treatment ward for radionuclide therapies of patients. Clinical trials are supported by a team of researchers within the department, that are highly experienced in the regulatory aspects of preforming clinical trials with radionuclides.

Services offered

  • Targeting agent and chelator development
  • Radiolabelling strategy and instrumentation for quality controls
  • Preclinical study
  • Chemical and radiochemical characterization
  • In vitro characterization of new radiotracers
  • In vivo characterization of new radiotracers
  • Toxicity/dosimetry studies
  • Regulatory documents
  • Radiopharmaceutical GMP manufacturing
  • Clinical trial

PRISMAP newsletter features

The editorial content of our newsletter is available on this page.